Swedish Clinic Finds Limited Eligibility for New Alzheimer Drugs
Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic https://t.co/H3TgYvgVSk
Mapping Genomic Landscape of Multiple Myeloma Precursors
Genomic landscape of multiple myeloma and its precursor conditions [May 21, 2025] Jean-Baptiste Alberge et al. @IrenemGhobrial @NatureGenet https://t.co/DDWGRrpI4Y #mmsm #PrecisionMedicine #cagenome https://t.co/X0OPLHNkdG
Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [Jan 15, 2026] @hollyleeYJ et al. @NBahlis @NatureMedicine https://t.co/mz393mPMAq #mmsm #PrecisionMedicine #tcellrx THREAD: https://t.co/lNX9b7LsnR HT @AuclairDan https://t.co/d0JNE6pb5x
Uridine Shields Neurons by Activating Mitochondrial K⁺ Channel
The Protective Effect of Uridine in a Rotenone-Induced Model of Parkinson’s Disease: The Role of the Mitochondrial ATP-Dependent Potassium Channel https://t.co/jBlSlgedWo
Deregulation Accelerates AI Drug Discovery Across Borders
Two articles were just published in English featuring Insilico and my OpenClaw noticed. Here is an interesting story. In 2017, before going into China, we set up Insilico Korea and I spent a considerable amount of time there trying to...
Blocking Gut “Signal Two” Expands Tregs, Curbs IBD
Blocking immune 'signal two' in the gut expands a specialized regulatory T cell population, suppressing intestinal inflammation and suggesting a new therapeutic approach for inflammatory bowel disease and related autoimmune conditions. immunology
AI's First Real Test: Designing Drugs at Isomorphic Labs
Isomorphic Labs Is About to Find Out If AI Can Actually Design a Drug https://t.co/vhQTwhIO85
MIB‑626 NMN Shows Lifespan Boost and New Mechanism
1. No living forever 🙈 2. Some MIB-626 (crystaline polymorph, pure NMN) human clinical trial results are in 😀 3. About to resubmit a revised mouse MIB-626 paper with Alice Kane, showing improved health measures + lifespan & a putative new mechanism...
NTLA Set to Unveil First In‑Vivo CRISPR Phase 3 Data
Here is a video of me entering my office tomorrow knowing that $NTLA is about to present the first-ever Phase 3 data of an In Vivo (!) CRISPR Gene Editing Program. Somehow - and after @adamfeuerstein’s🧵👇- I have a feeling...
GLP‑1s Spark Massive Consumer Biotech Revolution
GLP-1s have paved the way for massive consumer biotech Discussed in Lifespan and still rolling out as predicted
Nesprin‑2 Protein Blocks Heart Cancer, May Aid Other Tumors
Wondered why we don’t hear about heart cancer? Contraction-sensing Nesprin-2 protein is discovered to prevent heart cancer By causing cells to pulse (or adding in Nespirin) we might be able to treat cancer in other organs 👏 @ScienceMagazine https://t.co/A8fOuw31N2
Consumer Biotech Poised to Dominate, Telehealth Captures Value
I’ve said this before: I believe consumer biotech will become the most compelling sub-sector within biotech - without question - and one of the most attractive investment opportunities overall. At its core, this category targets products that slow or reverse aging,...
Russian Gene Therapy Claims to Extend Life to 150
Russian scientist in bombshell ageing drug claim after Putin discussed 'living to 150' The Russian gene-therapy treatment could benefit Putin and his inner circle. https://t.co/dunqBJEPxN https://t.co/sH2GNbRqSs
Nanophotonic Chips Finally Make the Proteome Visible
We sequence genomes and map transcriptomes with ease. Why is the proteome still invisible? Proteins are where biology actually happens. But until now, we have lacked the tools to read them at scale. @jendionne and her team are building nanophotonic chips that...
PBMs' Formulary Tactics Drive Billion‑Dollar Patient Costs
The same companies you say are denying claims, are the ones you prop up buying access to formularies. Tell your members to stop being afraid of the PBMs and the insurance companies that own them, or they own. Your...
GLP‑1 Drugs May Trigger New Restrictive Eating Disorders
"There is also compelling preliminary evidence suggesting that the use of these drugs [GLP-1] could exacerbate and lead to new diagnoses of restrictive eating disorders, including anorexia nervosa." @NEJM today https://t.co/PeTLgyRXiL
GLP‑1 Weight Loss Drugs Lower HRV, Raise Heart Rate
Reducing body weight with GLP-1 agonists isn't a free lunch: negative impacts on HRV, RHR GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons https://t.co/4QNy141TtK
NVO Shows Fewer AEs; LLY Wins on Lower COGS
The $NVO drug has fewer AEs (based on comparative discontinuation rates) - only real advantage $LLY has here is much lower COGS (small molecule vs poorly absorbed peptide).
Epigenetic Plasticity Enables Precision Targeting of Senescent Cells
Epigenetic regulation of cellular senescence "This review proposes a roadmap for leveraging epigenetic plasticity, offering a precision medicine approach to target specific senescent cell populations and extend health span." https://t.co/UAuBP8WEeR https://t.co/i0XzhPM0NB
Undetected Antibodies Can Undermine Phage Therapy Effectiveness
Hidden antibodies in patients can neutralize bacteriophages, limiting the effectiveness of phage therapy for drug-resistant infections and highlighting the need for pre-treatment antibody screening. infectiousdisease
Targeting iNOS‑IRG1 Binding Offers Precise Anti‑Inflammatory Therapy
A newly discovered interaction between iNOS and IRG1 proteins directly regulates inflammation, suggesting that targeting their physical binding could offer more precise therapies for Crohn's disease, arthritis, and cardiovascular conditions. immunology
Invest in Proven Canine Cardiac Reversal Biotech
I co-founded @RejuvenateBio & have enjoyed the science from day one. Cardiac disease reversal in dogs. 3 years of safety data. Zero safety signals. They’ve opened a unique opportunity for the biotech community to invest & secure equity at this early...
Human Genetic Optimization Funding Claim Is Pure Fantasy
From Mother Jones story on polygenic selection and embryo editing plans. Absolutely zero chance that human genetic optimization companies raised $36.5 billion in 2024. This number is fantasy. https://t.co/we6euyIMXv
Readout LOUD Interview Explores Kelonia and Eli Lilly
Our Readout LOUD interview with @BRobertsVC about Kelonia and $LLY in print form. https://t.co/DsfGxwcvS3 via @statnews
Scaling Cheap In‑Vivo Causal Testing for Age‑Related Diseases
AI has made hypothesis generation in bio cheap. Anyone can get an answer to ‘could this play a role in my disease’, but how do we go from ‘could’ to ‘does’? The scarce resource now is causal evidence to test hypotheses...
ER-100 Cleared for Trials; Safety Promising, Translation Uncertain
So far, the data suggest ER-100 should be safe in humans, and the FDA has cleared us to move into clinical trials. Translation from primates to humans is never guaranteed If it doesn’t work as hoped, we’ll learn & improve, just...
Vertical AI Beats Generic Models in Enzyme Engineering
Foundation models are powerful. They're also generic. And in industrial enzyme engineering, generic doesn't cut it. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ1GbK The industrial last mile of...
TRT Gel/Injection Shows More Adverse Events Than Clomiphene
Interesting retrospective chart-based study in VA population - TRT gel/injection vs. clomiphene for hypogonadism. Matched populations at baseline. Far higher rates of AEs with gel/injection vs. clomiphene. "TRT was associated with an increased incidence of mortality, CVA, CAD, hypertension,...
GPT-5 Autonomously Outperforms SOTA Protein Synthesis by 40%
More on our work with @OpenAI where GPT-5 ran our autonomous lab at @Ginkgo and beat state of the art by 40% in cell free protein synthesis 👇
Lilly Slides as FDA Plans Psychedelic Voucher Program
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics https://t.co/kWvYtFeif0 $LLY - 4% $NVO + 6% $REGN $AMGN $BBOT #biotech
New Psychedelic Trials Target Depression and PTSD
Compass Pathways’ psilocybin (COMP360) for treatment-resistant depression (TRD) Usona Institute’s psilocybin for major depressive disorder (MDD) Otsuka’s methylone (TSND-201) for PTSD
FDA Withholds Company Names Unlike Other CNPVs
why is the FDA not releasing the company names? They did for every other CNPV...
GPX4 Inhibitors Eradicate Senescent Tumor Cells, Boost Chemo Efficacy
GPX4 inhibitors discovered that kill "zombie" senescent cells from tumors (increased w/ chemoRx) and effective in multiple preclinical models vs cancer, a new potential strategy to pursue in clinical trials https://t.co/lYX7xkI9xF @NatureCellBio https://t.co/mxbjzRQPck
AI-Designed PRMT5 Inhibitor Nominated in UAE
Today marks a historic moment for Insilico and another world's first in AI-powered drug discovery. We nominated the first preclinical/developmental candidate in the UAE. It is also our 30th PCC/DC nominated in the past 5 years. 12 molecules reached clinical...
US Military's Flu Vaccine Legacy Undermined by Dropping Mandates
Motivated by the devastation the Spanish flu inflicted on WW1 troops, the US military was key in the development of #flu vaccine. Keeping troops battle ready is critical, which makes Hegseth's decision to drop mandatory flu shots ill-advised, Paul Friedrichs...
PMVP Poised for Sale After Strong Phase 2 Results
Some movement on $PMVP worth flagging. Strong Phase 2 results, the market gave zero credit. But something is stirring. Board just appointed Laurie Stelzer as Chairman. CFO track record across multiple major pharma buyouts. Clear corporate finance chops. PMVP might be prepping for...
Epigenetic Reset: Once Mocked,
From 2008-2024 I was accused of hyping (a common slur) for suggesting that changes to the epigenome might cause aging and that therapeutics could "allow us to reset the epigenome to a more youthful state." - Oberdoerffer & Sinclair...
Former FDA Staffer Cites Political Pressure Blocking Rare‑disease Drug Approval
Former FDA staffer - “I recently left FDA due to the political pressure I was receiving to withhold my recommendation for approval for a drug that was intended for a rare disease. I was part of a review division that...
One‑Person Crossover Shows Statin May Impair Workouts
Statin vs Placebo: N = 1 Randomized Crossover Study After posting prior content reviewing data on statins and the potential risk of muscle loss, I was flooded with comments from people saying statins "annihilated" their workouts. Now, I know the party...
Start Lifestyle Changes With GLP‑1, Not After Stopping
The GLP-1 weight regain studies everyone is citing have a quiet design flaw: in a lot of those trials, patients were put on a rigid reduced-calorie plan while on the drug, then told to keep following that same rigid plan...
Sun Pharma's $13B All‑Cash Offer Boosts Organon
M&A lift: Sun Pharma readies $13B all‑cash bid for Organon, bank‑financed; strategic fit in women’s health and US manufacturing. Competing bidders and regulatory risk persist. Trade: go long OGN on bid momentum, tighten stop. — Viktor Kopylov, PhD, CFA. More insights:...
FGF21 Shows Dual Action: Reduces Drinking, Shields Liver
The study validated FGF21-a liver-derived hormone currently in clinical trials for fatty liver disease “as a dual-action therapeutic that both curbs harmful drinking behaviors and protects against alcohol-related liver injury https://t.co/VdPZvQQ9qp
Meta-Analysis Flawed by Mixing Disparate Anti‑amyloid Agents
A harsh critique of the recent @cochranecollab meta-analysis of the anti-amyloid drugs for Alzheimer's disease https://t.co/EU4JMOVWkV 'These results and their overarching conclusion that “successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects in...
Continuous Glucose Monitoring Outperforms Self‑Monitoring in Type 2 Diabetes
A randomized trial of continuous glucose monitoring (CGM) vs self-monitoring for Type 2 diabetes on basal insulin and drug therapies shows superiority of CGM for gluocse regulation https://t.co/XUymGiov1c @TheLancetEndo https://t.co/lcjFDnEG6x
Alleged FDA Pressure Removes Study Confirming Long‑term Vaccine Efficacy
Vinay Prasad forced FDA scientists to withdraw a paper from Vaccine, the journal I am co-EIC of, because it showed that COVID vaccines work for everyone 6 months+. This is Gold Standard Science at Marty Makary’s FDA. Setting the Gold...
CAR‑T Turnaround: Kelonia’s LLY Deal Signals New Pharma Play
A VERY SPIRITED interview w/ Venrock VC Bryan Roberts re: Kelonia Therapeutics and its $LLY deal on this week's Readout LOUD podcast. A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts https://t.co/600DsE1cBm via @statnews
Scalable Hypothesis‑testing Datasets Will Drive Biology’s AI ROI
Which AI-enabling datasets will bring the biggest ROI in biology? One type will be "ways to confirm hypotheses at scale". @GordianBio is building atlases of how every expressed gene target affects organs suffering diseases of aging.
NIH Director Censors Routine Vaccine Study Over Personal Dislike
To be clear: @NIHDirector_Jay reportedly took issue with the study design, which is routine for evaluating vaccines post-market. Podcast Jay, who has no expertise in vaccine trials, decided unilaterally he didn’t like it & thus censored results of studies our...
Metformin Fails to Boost Walking Distance in PAD Patients
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial "Among people with PAD without diabetes, metformin did not improve 6-minute walk distance at 6-month follow-up compared with placebo. These results do not support metformin...
Psilocybin Reconfigures Cortical Inhibition via Interneuron Recruitment
wonky / important pre-clinial paper out of Alex Kwan's lab Psilocybin reshapes cortical inhibition through selective interneuron recruitment @kwanalexc https://t.co/OZX2cHDD94